The antibiotic, called Zerbaxa, is the first new antibiotic approved in the U.S. under the Generating Antibiotic Incentives Now Act to treat Gram-negative bacteria.
“Today is an important day for patients, and we are very pleased to arm physicians with Zerbaxa in the battle against Gram-negative bacteria, where few treatment options exist,” said Robert Perez, president and COO of Cubist.
This is the fourth new antibacterial drug approved by the FDA this year, and the second one from Cubist. That makes it the first time this century a company has delivered two new FDA-approved antibiotics in one year.
More articles on antibiotics:
Patients don’t understand the risks of unnecessary antibiotics
The easiest way to reduce antibiotic prescribing in children’s hospitals
Merck to acquire antibiotic developer Cubist for $9.5B
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.